Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 142
Filtrar
1.
J Virol ; 98(9): e0063524, 2024 Sep 17.
Artículo en Inglés | MEDLINE | ID: mdl-39158346

RESUMEN

Flavivirus infection capitalizes on cellular lipid metabolism to remodel the cellular intima, creating a specialized lipid environment conducive to viral replication, assembly, and release. The Japanese encephalitis virus (JEV), a member of the Flavivirus genus, is responsible for significant morbidity and mortality in both humans and animals. Currently, there are no effective antiviral drugs available to combat JEV infection. In this study, we embarked on a quest to identify anti-JEV compounds within a lipid compound library. Our research led to the discovery of two novel compounds, isobavachalcone (IBC) and corosolic acid (CA), which exhibit dose-dependent inhibition of JEV proliferation. Time-of-addition assays indicated that IBC and CA predominantly target the late stage of the viral replication cycle. Mechanistically, JEV nonstructural proteins 1 and 2A (NS1 and NS2A) impede 5'-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activation by obstructing the liver kinase B1 (LKB1)-AMPK interaction, resulting in decreased p-AMPK expression and a consequent upsurge in lipid synthesis. In contrast, IBC and CA may stimulate AMPK by binding to its active allosteric site, thereby inhibiting lipid synthesis essential for JEV replication and ultimately curtailing viral infection. Most importantly, in vivo experiments demonstrated that IBC and CA protected mice from JEV-induced mortality, significantly reducing viral loads in the brain and mitigating histopathological alterations. Overall, IBC and CA demonstrate significant potential as effective anti-JEV agents by precisely targeting AMPK-associated signaling pathways. These findings open new therapeutic avenues for addressing infections caused by Flaviviruses. IMPORTANCE: This study is the inaugural utilization of a lipid compound library in antiviral drug screening. Two lipid compounds, isobavachalcone (IBC) and corosolic acid (CA), emerged from the screening, exhibiting substantial inhibitory effects on the Japanese encephalitis virus (JEV) proliferation in vitro. In vivo experiments underscored their efficacy, with IBC and CA reducing viral loads in the brain and mitigating JEV-induced histopathological changes, effectively shielding mice from fatal JEV infection. Intriguingly, IBC and CA may activate 5'-adenosine monophosphate (AMP)-activated protein kinase (AMPK) by binding to its active site, curtailing the synthesis of lipid substances, and thus suppressing JEV proliferation. This indicates AMPK as a potential antiviral target. Remarkably, IBC and CA demonstrated suppression of multiple viruses, including Flaviviruses (JEV and Zika virus), porcine herpesvirus (pseudorabies virus), and coronaviruses (porcine deltacoronavirus and porcine epidemic diarrhea virus), suggesting their potential as broad-spectrum antiviral agents. These findings shed new light on the potential applications of these compounds in antiviral research.


Asunto(s)
Proteínas Quinasas Activadas por AMP , Antivirales , Virus de la Encefalitis Japonesa (Especie) , Encefalitis Japonesa , Metabolismo de los Lípidos , Replicación Viral , Animales , Metabolismo de los Lípidos/efectos de los fármacos , Replicación Viral/efectos de los fármacos , Virus de la Encefalitis Japonesa (Especie)/efectos de los fármacos , Virus de la Encefalitis Japonesa (Especie)/fisiología , Ratones , Antivirales/farmacología , Humanos , Encefalitis Japonesa/tratamiento farmacológico , Encefalitis Japonesa/virología , Proteínas Quinasas Activadas por AMP/metabolismo , Chalconas/farmacología , Triterpenos/farmacología , Proteínas no Estructurales Virales/metabolismo , Infecciones por Flavivirus/tratamiento farmacológico , Infecciones por Flavivirus/virología , Infecciones por Flavivirus/metabolismo , Flavivirus/efectos de los fármacos , Línea Celular
2.
Sci Rep ; 14(1): 20095, 2024 08 29.
Artículo en Inglés | MEDLINE | ID: mdl-39209987

RESUMEN

Usutu (USUV), West Nile (WNV), and Zika virus (ZIKV) are neurotropic arthropod-borne viruses (arboviruses) that cause severe neurological disease in humans. However, USUV-associated neurological disease is rare, suggesting a block in entry to or infection of the brain. We determined the replication, cell tropism and neurovirulence of these arboviruses in human brain tissue using a well-characterized human fetal organotypic brain slice culture model. Furthermore, we assessed the efficacy of interferon-ß and 2'C-methyl-cytidine, a synthetic nucleoside analogue, in restricting viral replication. All three arboviruses replicated within the brain slices, with WNV reaching the highest titers, and all primarily infected neuronal cells. USUV- and WNV-infected cells exhibited a shrunken morphology, not associated with detectable cell death. Pre-treatment with interferon-ß inhibited replication of all arboviruses, while 2'C-methyl-cytidine reduced only USUV and ZIKV titers. Collectively, USUV can infect human brain tissue, showing similarities in tropism and neurovirulence as WNV and ZIKV. These data suggest that a blockade to infection of the human brain may not be the explanation for the low clinical incidence of USUV-associated neurological disease. However, USUV replicated more slowly and to lower titers than WNV, which could help to explain the reduced severity of neurological disease resulting from USUV infection.


Asunto(s)
Encéfalo , Flavivirus , Replicación Viral , Virus del Nilo Occidental , Virus Zika , Humanos , Virus del Nilo Occidental/patogenicidad , Virus del Nilo Occidental/fisiología , Virus Zika/patogenicidad , Virus Zika/fisiología , Encéfalo/virología , Replicación Viral/efectos de los fármacos , Flavivirus/patogenicidad , Flavivirus/fisiología , Flavivirus/efectos de los fármacos , Feto/virología , Interferón beta/farmacología , Animales , Virulencia , Técnicas de Cultivo de Órganos , Tropismo Viral , Neuronas/virología , Infecciones por Flavivirus/virología , Infección por el Virus Zika/virología , Chlorocebus aethiops , Células Vero
3.
Virus Res ; 348: 199447, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39117146

RESUMEN

One third of all emerging infectious diseases are vector-borne, with no licensed antiviral therapies available against any vector-borne viruses. Zika virus and Usutu virus are two emerging flaviviruses transmitted primarily by mosquitoes. These viruses modulate different host pathways, including the PI3K/AKT/mTOR pathway. Here, we report the effect on ZIKV and USUV replication of two AKT inhibitors, Miransertib (ARQ-092, allosteric inhibitor) and Capivasertib (AZD5363, competitive inhibitor) in different mammalian and mosquito cell lines. Miransertib showed a stronger inhibitory effect against ZIKV and USUV than Capivasertib in mammalian cells, while Capivasertib showed a stronger effect in mosquito cells. These findings indicate that AKT plays a conserved role in flavivirus infection, in both the vertebrate host and invertebrate vector. Nevertheless, the specific function of AKT may vary depending on the host species. These findings indicate that AKT may be playing a conserved role in flavivirus infection in both, the vertebrate host and the invertebrate vector. However, the specific function of AKT may vary depending on the host species. A better understanding of virus-host interactions is therefore required to develop new treatments to prevent human disease and new approaches to control transmission by insect vectors.


Asunto(s)
Infecciones por Flavivirus , Flavivirus , Proteínas Proto-Oncogénicas c-akt , Replicación Viral , Virus Zika , Animales , Flavivirus/fisiología , Flavivirus/efectos de los fármacos , Flavivirus/genética , Humanos , Proteínas Proto-Oncogénicas c-akt/metabolismo , Proteínas Proto-Oncogénicas c-akt/genética , Línea Celular , Virus Zika/fisiología , Virus Zika/efectos de los fármacos , Infecciones por Flavivirus/virología , Infecciones por Flavivirus/transmisión , Vertebrados/virología , Antivirales/farmacología , Mosquitos Vectores/virología , Chlorocebus aethiops , Culicidae/virología , Interacciones Huésped-Patógeno
4.
Nat Commun ; 15(1): 5179, 2024 Jun 19.
Artículo en Inglés | MEDLINE | ID: mdl-38898037

RESUMEN

Viral genetic diversity presents significant challenges in developing antivirals with broad-spectrum activity and high barriers to resistance. Here we report development of proteolysis targeting chimeras (PROTACs) targeting the dengue virus envelope (E) protein through coupling of known E fusion inhibitors to ligands of the CRL4CRBN E3 ubiquitin ligase. The resulting small molecules block viral entry through inhibition of E-mediated membrane fusion and interfere with viral particle production by depleting intracellular E in infected Huh 7.5 cells. This activity is retained in the presence of point mutations previously shown to confer partial resistance to the parental inhibitors due to decreased inhibitor-binding. The E PROTACs also exhibit broadened spectrum of activity compared to the parental E inhibitors against a panel of mosquito-borne flaviviruses. These findings encourage further exploration of targeted protein degradation as a differentiated and potentially advantageous modality for development of broad-spectrum direct-acting antivirals.


Asunto(s)
Antivirales , Virus del Dengue , Flavivirus , Proteolisis , Internalización del Virus , Humanos , Proteolisis/efectos de los fármacos , Animales , Antivirales/farmacología , Flavivirus/efectos de los fármacos , Flavivirus/genética , Flavivirus/metabolismo , Internalización del Virus/efectos de los fármacos , Virus del Dengue/efectos de los fármacos , Virus del Dengue/fisiología , Virus del Dengue/genética , Culicidae/virología , Ubiquitina-Proteína Ligasas/metabolismo , Proteínas del Envoltorio Viral/metabolismo , Línea Celular
5.
ACS Appl Bio Mater ; 7(5): 2862-2871, 2024 05 20.
Artículo en Inglés | MEDLINE | ID: mdl-38699864

RESUMEN

Mosquito-borne viruses are a major worldwide health problem associated with high morbidity and mortality rates and significant impacts on national healthcare budgets. The development of antiviral drugs for both the treatment and prophylaxis of these diseases is thus of considerable importance. To address the need for therapeutics with antiviral activity, a library of heparan sulfate mimetic polymers was screened against dengue virus (DENV), Yellow fever virus (YFV), Zika virus (ZIKV), and Ross River virus (RRV). The polymers were prepared by RAFT polymerization of various acidic monomers with a target MW of 20 kDa (average Mn ∼ 27 kDa by GPC). Among the polymers, poly(SS), a homopolymer of sodium styrenesulfonate, was identified as a broad spectrum antiviral with activity against all the tested viruses and particularly potent inhibition of YFV (IC50 = 310 pM). Our results further uncovered that poly(SS) exhibited a robust inhibition of ZIKV infection in both mosquito and human cell lines, which points out the potential functions of poly(SS) in preventing mosquito-borne viruses associated diseases by blocking viral transmission in their mosquito vectors and mitigating viral infection in patients.


Asunto(s)
Antivirales , Biomimética , Flavivirus , Heparitina Sulfato , Mosquitos Vectores , Poliestirenos , Virus del Río Ross , Poliestirenos/farmacología , Poliestirenos/uso terapéutico , Heparitina Sulfato/química , Antivirales/farmacología , Antivirales/uso terapéutico , Virus del Río Ross/efectos de los fármacos , Flavivirus/efectos de los fármacos , Relación Estructura-Actividad , Células A549 , Humanos , Animales , Mosquitos Vectores/virología
6.
Antiviral Res ; 226: 105878, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38582134

RESUMEN

Flaviviruses can cause severe illness in humans. Effective and safe vaccines are available for some species; however, for many flaviviruses disease prevention or specific treatments remain unavailable. The viral replication cycle depends on the proteolytic activity of the NS2B-NS3 protease, which releases functional viral proteins from a non-functional polyprotein precursor, rendering the protease a promising drug target. In this study, we characterised recombinant NS2B-NS3 proteases from ten flaviviruses including three unreported proteases from the Usutu, Kyasanur forest disease and Powassan viruses. All protease constructs comprise a covalent Gly4-Ser-Gly4 linker connecting the NS3 serine protease domain with its cofactor NS2B. We conducted a comprehensive cleavage site analysis revealing areas of high conversion. While all proteases were active in enzymatic assays, we noted a 1000-fold difference in catalytic efficiency across proteases from different flaviviruses. Two bicyclic peptide inhibitors displayed anti-pan-flaviviral protease activity with inhibition constants ranging from 10 to 1000 nM.


Asunto(s)
Antivirales , Flavivirus , Serina Endopeptidasas , Proteínas no Estructurales Virales , Proteínas no Estructurales Virales/metabolismo , Proteínas no Estructurales Virales/química , Proteínas no Estructurales Virales/genética , Flavivirus/efectos de los fármacos , Flavivirus/enzimología , Serina Endopeptidasas/metabolismo , Serina Endopeptidasas/química , Antivirales/farmacología , Antivirales/química , Humanos , ARN Helicasas/metabolismo , ARN Helicasas/química , ARN Helicasas/genética , Inhibidores de Proteasas/farmacología , Inhibidores de Proteasas/química , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/química , Proteasas Virales , Nucleósido-Trifosfatasa , ARN Helicasas DEAD-box
7.
J Cell Biochem ; 124(1): 127-145, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-36502494

RESUMEN

Numerous pathogens affecting human is present in the flavivirus family namely west nile, dengue, yellow fever, and zika which involves in development of global burden and distressing the environment economically. Till date, no approved drugs are available for targeting these viruses. The threat which urged the identification of small molecules for the inhibition of these viruses is the spreading of serious viral diseases. The recent outbreak of zika and dengue infections postured a solemn risk to worldwide public well-being. RNA-dependent RNA polymerase (RdRp) is the supreme adaptable enzymes of all the RNA viruses which is responsible for the replication and transcription of genome among the structural and nonstructural proteins of flaviviruses. It is understood that the RdRp of the flaviviruses are similar stating that the japanese encephalitis and west nile shares 70% identity with zika whereas the dengue serotype 2 and 3 shares the identity of 76% and 81%, respectively. In this study, we investigated the binding site of four flaviviral RdRp and provided insights into various interaction of the molecules using the computational approach. Our study helps in recognizing the potent compounds that could inhibit the viral protein as a common inhibitor. Additionally, with the conformational stability analysis, we proposed the possible mechanism of inhibition of the identified common small molecule toward RdRp of flavivirus. Finally, this study could be an initiative for the identification of common inhibitors and can be explored further for understanding the mechanism of action through in vitro studies for the study on efficacy.


Asunto(s)
Reposicionamiento de Medicamentos , Flavivirus , ARN Polimerasa Dependiente del ARN , Humanos , Dengue/tratamiento farmacológico , Flavivirus/efectos de los fármacos , Flavivirus/enzimología , ARN Polimerasa Dependiente del ARN/antagonistas & inhibidores , ARN Polimerasa Dependiente del ARN/metabolismo , Proteínas Virales/metabolismo , Virus Zika/efectos de los fármacos , Virus Zika/enzimología , Infección por el Virus Zika/tratamiento farmacológico
8.
Antiviral Res ; 202: 105325, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-35460703

RESUMEN

Epidemics caused by flaviviruses occur globally; however, no antiviral drugs treating flaviviruses infections have yet been developed. Nafamostat (NM) is a protease inhibitor approved for pancreatitis and anti-coagulation. The anti-flavivirus potential of NM has yet to be determined. Here, utilizing in vitro and in vivo infection assays, we present that NM effectively inhibits Zika virus (ZIKV) and other flaviviruses in vitro. NM inhibited the production of ZIKV viral RNA and proteins originating from Asia and African lineage in human-, mouse- and monkey-derived cell lines and the in vivo anti-ZIKV efficacy of NM was verified. Mode-of-action analysis using time-of-drug-addition assay, infectivity inhibition assay, surface plasmon resonance assay, and molecular docking revealed that NM interacted with viral particles and blocked the early stage of infection by targeting the domain III of ZIKV envelope protein. Analysing the anti-flavivirus effects of NM-related compounds suggested that the antiviral effect depended on the unique structure of NM. These findings suggest the potential use of NM as an anti-flavivirus candidate, and a novel drug design approach targeting the flavivirus envelope protein.


Asunto(s)
Antivirales , Benzamidinas , Flavivirus , Guanidinas , Virus Zika , Animales , Antivirales/química , Antivirales/farmacología , Benzamidinas/química , Benzamidinas/farmacología , Flavivirus/efectos de los fármacos , Guanidinas/química , Guanidinas/farmacología , Haplorrinos , Humanos , Ratones , Simulación del Acoplamiento Molecular , Proteínas del Envoltorio Viral/metabolismo , Virus Zika/efectos de los fármacos
9.
J Virol ; 96(4): e0177821, 2022 02 23.
Artículo en Inglés | MEDLINE | ID: mdl-34908449

RESUMEN

RNA interference (RNAi) functions as the major host antiviral defense in insects, while less is understood about how to utilize antiviral RNAi in controlling viral infection in insects. Enoxacin belongs to the family of synthetic antibacterial compounds based on a fluoroquinolone skeleton that has been previously found to enhance RNAi in mammalian cells. In this study, we show that enoxacin efficiently inhibited viral replication of Drosophila C virus (DCV) and cricket paralysis virus (CrPV) in cultured Drosophila cells. Enoxacin promoted the loading of Dicer-2-processed virus-derived small interfering RNA (siRNA) into the RNA-induced silencing complex, thereby enhancing the antiviral RNAi response in infected cells. Moreover, enoxacin treatment elicited RNAi-dependent in vivo protective efficacy against DCV or CrPV challenge in adult fruit flies. In addition, enoxacin also inhibited the replication of flaviviruses, including dengue virus and Zika virus, in Aedes mosquito cells in an RNAi-dependent manner. Together, our findings demonstrate that enoxacin can enhance RNAi in insects, and enhancing RNAi by enoxacin is an effective antiviral strategy against diverse viruses in insects, which may be exploited as a broad-spectrum antiviral agent to control the vector transmission of arboviruses or viral diseases in insect farming. IMPORTANCE RNAi has been widely recognized as one of the most broadly acting and robust antiviral mechanisms in insects. However, the application of antiviral RNAi in controlling viral infections in insects is less understood. Enoxacin is a fluoroquinolone compound that was previously found to enhance RNAi in mammalian cells, while its RNAi-enhancing activity has not been assessed in insects. Here, we show that enoxacin treatment inhibited viral replication of DCV and CrPV in Drosophila cells and adult fruit flies. Enoxacin promoted the loading of Dicer-generated virus-derived siRNA into the Ago2-incorporated RNA-induced silencing complex and in turn strengthened the antiviral RNAi response in the infected cells. Moreover, enoxacin displayed effective RNAi-dependent antiviral effects against flaviviruses, such as dengue virus and Zika virus, in mosquito cells. This study is the first to demonstrate that enhancing RNAi by enoxacin elicits potent antiviral effects against diverse viruses in insects.


Asunto(s)
Antivirales/farmacología , Enoxacino/farmacología , Virus de Insectos/efectos de los fármacos , Interferencia de ARN/efectos de los fármacos , Aedes , Animales , Línea Celular , Drosophila , Flavivirus/clasificación , Flavivirus/efectos de los fármacos , Virus de Insectos/clasificación , ARN Interferente Pequeño/metabolismo , ARN Viral/metabolismo , Complejo Silenciador Inducido por ARN/metabolismo , Replicación Viral/efectos de los fármacos
10.
J Virol ; 96(2): e0177421, 2022 01 26.
Artículo en Inglés | MEDLINE | ID: mdl-34757841

RESUMEN

Alphaviruses and flaviviruses have class II fusion glycoproteins that are essential for virion assembly and infectivity. Importantly, the tip of domain II is structurally conserved between the alphavirus and flavivirus fusion proteins, yet whether these structural similarities between virus families translate to functional similarities is unclear. Using in vivo evolution of Zika virus (ZIKV), we identified several novel emerging variants, including an envelope glycoprotein variant in ß-strand c (V114M) of domain II. We have previously shown that the analogous ß-strand c and the ij loop, located in the tip of domain II of the alphavirus E1 glycoprotein, are important for infectivity. This led us to hypothesize that flavivirus E ß-strand c also contributes to flavivirus infection. We generated this ZIKV glycoprotein variant and found that while it had little impact on infection in mosquitoes, it reduced replication in human cells and mice and increased virus sensitivity to ammonium chloride, as seen for alphaviruses. In light of these results and given our alphavirus ij loop studies, we mutated a conserved alanine at the tip of the flavivirus ij loop to valine to test its effect on ZIKV infectivity. Interestingly, this mutation inhibited infectious virion production of ZIKV and yellow fever virus, but not West Nile virus. Together, these studies show that shared domains of the alphavirus and flavivirus class II fusion glycoproteins harbor structurally analogous residues that are functionally important and contribute to virus infection in vivo.IMPORTANCE Arboviruses are a significant global public health threat, yet there are no antivirals targeting these viruses. This problem is in part due to our lack of knowledge of the molecular mechanisms involved in the arbovirus life cycle. In particular, virus entry and assembly are essential processes in the virus life cycle and steps that can be targeted for the development of antiviral therapies. Therefore, understanding common, fundamental mechanisms used by different arboviruses for entry and assembly is essential. In this study, we show that flavivirus and alphavirus residues located in structurally conserved and analogous regions of the class II fusion proteins contribute to common mechanisms of entry, dissemination, and infectious-virion production. These studies highlight how class II fusion proteins function and provide novel targets for development of antivirals.


Asunto(s)
Alphavirus/fisiología , Flavivirus/fisiología , Proteínas Virales de Fusión/metabolismo , Virión/metabolismo , Replicación Viral , Células A549 , Alphavirus/efectos de los fármacos , Cloruro de Amonio/farmacología , Animales , Culicidae/virología , Flavivirus/efectos de los fármacos , Humanos , Interferón Tipo I/deficiencia , Ratones , Ratones Mutantes , Mutación , Dominios Proteicos , Proteínas Virales de Fusión/química , Proteínas Virales de Fusión/genética , Proteínas no Estructurales Virales/química , Proteínas no Estructurales Virales/genética , Proteínas no Estructurales Virales/metabolismo , Virión/genética , Ensamble de Virus/genética , Internalización del Virus/efectos de los fármacos , Replicación Viral/genética , Virus Zika/efectos de los fármacos , Virus Zika/fisiología , Infección por el Virus Zika/virología
11.
Viruses ; 13(10)2021 10 02.
Artículo en Inglés | MEDLINE | ID: mdl-34696411

RESUMEN

Viral proteases are indispensable for successful virion maturation, thus making them a prominent drug target. Their enzyme activity is tightly spatiotemporally regulated by expression in the precursor form with little or no activity, followed by activation via autoprocessing. These cleavage events are frequently triggered upon transportation to a specific compartment inside the host cell. Typically, precursor oligomerization or the presence of a co-factor is needed for activation. A detailed understanding of these mechanisms will allow ligands with non-canonical mechanisms of action to be designed, which would specifically modulate the initial irreversible steps of viral protease autoactivation. Binding sites exclusive to the precursor, including binding sites beyond the protease domain, can be exploited. Both inhibition and up-regulation of the proteolytic activity of viral proteases can be detrimental for the virus. All these possibilities are discussed using examples of medically relevant viruses including herpesviruses, adenoviruses, retroviruses, picornaviruses, caliciviruses, togaviruses, flaviviruses, and coronaviruses.


Asunto(s)
Antivirales/farmacología , Inhibidores de Proteasa Viral/farmacología , Proteasas Virales/metabolismo , Virosis/tratamiento farmacológico , Adenovirus Humanos/efectos de los fármacos , Adenovirus Humanos/metabolismo , Flavivirus/efectos de los fármacos , Flavivirus/metabolismo , VIH-1/efectos de los fármacos , Herpesviridae/efectos de los fármacos , Herpesviridae/metabolismo , Humanos , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/metabolismo , Proteasas Virales/biosíntesis
12.
Molecules ; 26(20)2021 Oct 14.
Artículo en Inglés | MEDLINE | ID: mdl-34684782

RESUMEN

Viral infections are among the most complex medical problems and have been a major threat to the economy and global health. Several epidemics and pandemics have occurred due to viruses, which has led to a significant increase in mortality and morbidity rates. Natural products have always been an inspiration and source for new drug development because of their various uses. Among all-natural sources, plant sources are the most dominant for the discovery of new therapeutic agents due to their chemical and structural diversity. Despite the traditional use and potential source for drug development, natural products have gained little attention from large pharmaceutical industries. Several plant extracts and isolated compounds have been extensively studied and explored for antiviral properties against different strains of viruses. In this review, we have compiled antiviral plant extracts and natural products isolated from plants reported since 2015.


Asunto(s)
Antivirales/aislamiento & purificación , Antivirales/farmacología , Productos Biológicos/farmacología , Desarrollo de Medicamentos , Extractos Vegetales/farmacología , Animales , Fármacos Anti-VIH/química , Fármacos Anti-VIH/aislamiento & purificación , Fármacos Anti-VIH/farmacología , Antivirales/química , Productos Biológicos/química , Productos Biológicos/aislamiento & purificación , Descubrimiento de Drogas , Flavivirus/efectos de los fármacos , Virus de Hepatitis/efectos de los fármacos , Humanos , Estructura Molecular , Orthomyxoviridae/efectos de los fármacos , Extractos Vegetales/química , Simplexvirus/efectos de los fármacos
13.
Eur J Med Chem ; 224: 113683, 2021 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-34273661

RESUMEN

The worldwide circulation of different viruses coupled with the increased frequency and diversity of new outbreaks, strongly highlight the need for new antiviral drugs to quickly react against potential pandemic pathogens. Broad-spectrum antiviral agents (BSAAs) represent the ideal option for a prompt response against multiple viruses, new and re-emerging. Starting from previously identified anti-flavivirus hits, we report herein the identification of promising BSAAs by submitting the multi-target 2,6-diaminopurine chemotype to a system-oriented optimization based on phenotypic screening on cell cultures infected with different viruses. Among the synthesized compounds, 6i showed low micromolar potency against Dengue, Zika, West Nile and Influenza A viruses (IC50 = 0.5-5.3 µM) with high selectivity index. Interestingly, 6i also inhibited SARS-CoV-2 replication in different cell lines, with higher potency on Calu-3 cells that better mimic the SARS-CoV-2 infection in vivo (IC50 = 0.5 µM, SI = 240). The multi-target effect of 6i on flavivirus replication was also analyzed in whole cell studies (in vitro selection and immunofluorescence) and against isolated host/viral targets.


Asunto(s)
Antivirales/química , Antivirales/farmacología , Flavivirus/efectos de los fármacos , Orthomyxoviridae/efectos de los fármacos , Purinas/química , Purinas/farmacología , SARS-CoV-2/efectos de los fármacos , Terapia Molecular Dirigida , Replicación Viral/efectos de los fármacos
14.
Viruses ; 13(5)2021 05 12.
Artículo en Inglés | MEDLINE | ID: mdl-34066055

RESUMEN

Arthropod-borne flaviviruses, such as Zika virus (ZIKV), Usutu virus (USUV), and West Nile virus (WNV), are a growing cause of human illness and death around the world. Presently, no licensed antivirals to control them are available and, therefore, search for broad-spectrum antivirals, including host-directed compounds, is essential. The PI3K/Akt pathway controls essential cellular functions involved in cell metabolism and proliferation. Moreover, Akt has been found to participate in modulating replication in different viruses including the flaviviruses. In this work we studied the interaction of flavivirus NS5 polymerases with the cellular kinase Akt. In vitro NS5 phosphorylation experiments with Akt showed that flavivirus NS5 polymerases are phosphorylated and co-immunoprecipitate by Akt. Polymerase activity assays of Ala- and Glu-generated mutants for the Akt-phosphorylated residues also indicate that Glu mutants of ZIKV and USUV NS5s present a reduced primer-extension activity that was not observed in WNV mutants. Furthermore, treatment with Akt inhibitors (MK-2206, honokiol and ipatasertib) reduced USUV and ZIKV titers in cell culture but, except for honokiol, not WNV. All these findings suggest an important role for Akt in flavivirus replication although with specific differences among viruses and encourage further investigations to examine the PI3K/Akt/mTOR pathway as an antiviral potential target.


Asunto(s)
Infecciones por Flavivirus/metabolismo , Infecciones por Flavivirus/virología , Flavivirus/fisiología , Interacciones Huésped-Patógeno , Proteínas Proto-Oncogénicas c-akt/metabolismo , Proteínas no Estructurales Virales/metabolismo , Replicación Viral , Animales , Flavivirus/efectos de los fármacos , Genoma Viral , Humanos , Mutación , Sistemas de Lectura Abierta , Fosfatidilinositol 3-Quinasas/metabolismo , Fosforilación , Unión Proteica , Proteoma , Proteómica/métodos , ARN Polimerasa Dependiente del ARN/genética , ARN Polimerasa Dependiente del ARN/metabolismo , Proteínas no Estructurales Virales/genética , Virus del Nilo Occidental/fisiología , Virus Zika/fisiología , Infección por el Virus Zika/metabolismo , Infección por el Virus Zika/virología
15.
Nat Commun ; 12(1): 3266, 2021 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-34075032

RESUMEN

The epidemic emergence of relatively rare and geographically isolated flaviviruses adds to the ongoing disease burden of viruses such as dengue. Structural analysis is key to understand and combat these pathogens. Here, we present a chimeric platform based on an insect-specific flavivirus for the safe and rapid structural analysis of pathogenic viruses. We use this approach to resolve the architecture of two neurotropic viruses and a structure of dengue virus at 2.5 Å, the highest resolution for an enveloped virion. These reconstructions allow improved modelling of the stem region of the envelope protein, revealing two lipid-like ligands within highly conserved pockets. We show that these sites are essential for viral growth and important for viral maturation. These findings define a hallmark of flavivirus virions and a potential target for broad-spectrum antivirals and vaccine design. We anticipate the chimeric platform to be widely applicable for investigating flavivirus biology.


Asunto(s)
Infecciones por Flavivirus/terapia , Flavivirus/ultraestructura , Proteínas del Envoltorio Viral/ultraestructura , Virión/ultraestructura , Aedes/virología , Animales , Antivirales/farmacología , Antivirales/uso terapéutico , Línea Celular , Chlorocebus aethiops , Microscopía por Crioelectrón , Dengue/terapia , Dengue/virología , Vacunas contra el Dengue/administración & dosificación , Vacunas contra el Dengue/farmacología , Diseño de Fármacos , Flavivirus/efectos de los fármacos , Flavivirus/inmunología , Flavivirus/patogenicidad , Infecciones por Flavivirus/virología , Humanos , Mesocricetus , Modelos Moleculares , Conformación Molecular , Mutagénesis Sitio-Dirigida , Mutación Puntual , Células Vero , Proteínas del Envoltorio Viral/metabolismo , Vacunas Virales/farmacología , Vacunas Virales/uso terapéutico , Virión/efectos de los fármacos , Virión/metabolismo
16.
Curr Opin Virol ; 49: 164-175, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-34171540

RESUMEN

The flavivirus are emerging and re-emerging arthropod-borne pathogens responsible for significant mortality and morbidity worldwide. The genus comprises more than 70 viruses, and despite genomic and structural similarities, infections by different flaviviruses result in different clinical presentations. In the absence of a safe and effective vaccine against these infections, the search for new strategies to inhibit viral infection is necessary. The life cycle of arboviruses begins with the entry process composed of multiple steps: attachment, internalization, endosomal escape and capsid uncoating. This mini-review describes factors and mechanisms involved in the viral entry as events required to take over the cellular machinery and host factors and cellular pathways commonly used by flaviviruses as possible approaches for developing broad-spectrum antiviral drugs.


Asunto(s)
Infecciones por Flavivirus/virología , Flavivirus/fisiología , Internalización del Virus , Animales , Antivirales/metabolismo , Antivirales/farmacología , Endocitosis , Flavivirus/efectos de los fármacos , Flavivirus/patogenicidad , Infecciones por Flavivirus/tratamiento farmacológico , Interacciones Huésped-Patógeno , Humanos , Receptores Virales/metabolismo , Proteínas del Envoltorio Viral/química , Proteínas del Envoltorio Viral/metabolismo , Internalización del Virus/efectos de los fármacos , Replicación Viral
17.
Poult Sci ; 100(4): 100989, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33647721

RESUMEN

The duck Tembusu virus (DTMUV) is a novel mosquito-borne Flavivirus which caused huge economic losses for poultry industries in Southeast Asia and China. Currently, no effective antiviral drugs against this virus have been reported. (-)-Epigallocatechin-3-gallate (EGCG), a polyphenol present in abundance in green tea, has recently been demonstrated to have an antiviral activity for many viruses; however, whether EGCG can inhibit DTMUV infection remains unknown. Here, we tried to explore the anti-DTMUV effects and mechanisms of EGCG both in vitro and in vivo. Several EGCG treatment regimens were used to study the comprehensive antiviral activity of EGCG in DTMUV-infected baby hamster kidney cell line (BHK-21). The DTMUV titers of mock- and EGCG-treated infected cell cultures were determined using the tissue culture infective dose assay and the DTMUV mRNA copy number as determined using quantitative Real Time PCR. Moreover, the therapeutic efficacy of EGCG against DTMUV was assessed in DTMUV-infected ducklings. Our results suggested that EGCG significantly reduced the viral infection in BHK-21 cells in a dose-dependent manner, as reflected by the reduction of virus titers, virus copy number, and the expressions of viral E protein. We also observed that EGCG exhibited direct virucidal abilities against DTMUV. Notably, a significant reduction in virus binding ability was also observed, indicating that EGCG possesses excellent inhibitory effects on the viral adsorption step. In addition, DTMUV replication was also suppressed in BHK-21 cells treated with EGCG after viral entry, likely because of upregulation of the levels of interferon alfa and interferon beta. Finally, we also proved that EGCG exhibited anti-DTMUV efficacy in a duckling infection model because the survival rate was significantly improved. This is the first study to demonstrate the protective effect of EGCG against DTMUV, suggesting its potential use as an antiviral drug for DTMUV infection.


Asunto(s)
Catequina/análogos & derivados , Infecciones por Flavivirus , Flavivirus , Interferón Tipo I , Enfermedades de las Aves de Corral , Internalización del Virus , Animales , Antivirales/farmacología , Antivirales/uso terapéutico , Catequina/farmacología , Línea Celular , China , Cricetinae , Patos , Flavivirus/efectos de los fármacos , Infecciones por Flavivirus/tratamiento farmacológico , Infecciones por Flavivirus/veterinaria , Interferón Tipo I/genética , Enfermedades de las Aves de Corral/tratamiento farmacológico , Análisis de Supervivencia , Resultado del Tratamiento , Regulación hacia Arriba/efectos de los fármacos , Internalización del Virus/efectos de los fármacos
18.
Arch Virol ; 166(5): 1433-1438, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-33683474

RESUMEN

The recent introduction of Zika virus (ZIKV), the recurrence of dengue virus (DENV), and the lethality of yellow fever virus (YFV) have had a significant impact on Brazilian society and public health. Here, we targeted two cellular kinases implicated in cell proliferation and cancer that are also important for viral replication: mitogen-activated protein kinase kinase (MEK) and Src. We used two MEK inhibitors - trametinib and selumetinib - and two Src inhibitors - saracatinib and bosutinib - to inhibit ZIKV, DENV, and YFV replication in cell culture. The cytotoxicity of the four inhibitors was determined by the observation of abnormal morphology and quantification of adherent cells by crystal violet staining. The antiviral activity of these drugs was assessed based on the reduction of plaque-forming units in cell culture as evidence of the inhibition of the replication of the selected flaviviruses. All four inhibitors showed antiviral activity, but among them, trametinib was the safest and most efficacious against all of the viruses, inhibiting the replication of ZIKV and YFV by 1000-fold, and DENV2/3 by nearly 100-fold. This pan-antiviral effect shows that trametinib could be repurposed for the treatment of flaviviral infections.


Asunto(s)
Antivirales/farmacología , Flavivirus/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Chlorocebus aethiops , Cricetinae , Flavivirus/clasificación , Flavivirus/fisiología , Quinasas de Proteína Quinasa Activadas por Mitógenos/antagonistas & inhibidores , Células Vero , Replicación Viral/efectos de los fármacos , Familia-src Quinasas/antagonistas & inhibidores
19.
Eur J Med Chem ; 210: 112992, 2021 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-33208235

RESUMEN

The mosquito-borne viruses belonging to the genus Flavivirus such as Dengue virus (DENV) and Zika virus (ZIKV) cause human infections ranging from mild flu-like symptoms to hemorrhagic fevers, hepatitis, and neuropathies. To date, there are vaccines only for few flaviviruses while no effective treatments are available. Pyridobenzothiazole (PBTZ) derivatives are a class of compounds endowed with a promising broad-spectrum anti-flavivirus activity and most of them have been reported as potent inhibitors of the flaviviral NS5 polymerase. However, synthesis of PBTZ analogues entails a high number of purification steps, the use of hazardous reagents and environmentally unsustainable generation of waste. Considering the promising antiviral activity of PBTZ analogues which require further exploration, in this work, we report the development of a new and sustainable three-component reaction (3CR) that can be combined with a basic hydrolysis in a one-pot procedure to obtain the PBTZ scaffold, thus reducing the number of synthetic steps, improving yields and saving time. 3CR was significantly explored in order to demonstrate its wide scope by using different starting materials. In addition, taking advantage of these procedures, we next designed and synthesized a new set of PBTZ analogues that were tested as anti-DENV-2 and anti-ZIKV agents. Compound 22 inhibited DENV-2 NS5 polymerase with an IC50 of 10.4 µM and represented the best anti-flavivirus compound of the new series by inhibiting DENV-2- and ZIKV-infected cells with EC50 values of 1.2 and 5.0 µM, respectively, that translates into attractive selectivity indexes (SI - 83 and 20, respectively). These results strongly reaffirm PBTZ derivatives as promising anti-flavivirus agents that now can be synthesized through a convenient and sustainable 3CR in order to obtain more potent compounds for further pre-clinical development studies.


Asunto(s)
Antivirales/farmacología , Benzotiazoles/farmacología , Flavivirus/efectos de los fármacos , Antivirales/síntesis química , Antivirales/química , Benzotiazoles/síntesis química , Benzotiazoles/química , Relación Dosis-Respuesta a Droga , Humanos , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Relación Estructura-Actividad
20.
Methods Mol Biol ; 2233: 93-100, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33222129

RESUMEN

Endocytosis is a vesicle-based mechanism by which eukaryotic cells internalize extracellular material. There are several types of this universal mechanism linked to different types of endocytosed cargo, including pathogens; therefore, several approaches can be applied. Here, we describe techniques that are applicable to study the internalization of flaviviruses; dextrans; transporters, such as, glutamate transporter vGlut1; and peptidergic signaling molecules, including atrial natriuretic peptide into astrocytes, the most heterogeneous neuroglial cells, which play a key homeostatic role in the central nervous system.


Asunto(s)
Factor Natriurético Atrial/genética , Endocitosis/genética , Biología Molecular/métodos , Transporte de Proteínas/genética , Astrocitos/metabolismo , Astrocitos/microbiología , Astrocitos/virología , Factor Natriurético Atrial/farmacología , Calcio/metabolismo , Flavivirus/efectos de los fármacos , Humanos , Orgánulos/genética , Orgánulos/metabolismo , Orgánulos/virología , Internalización del Virus/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA